Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-3605 + INO-3609
- Development stage
- Unknown
- Lead developer
- Inovio Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
INO-3605 + INO-3609 is a combination DNA vaccine developed by Inovio Pharmaceuticals for the prevention of influenza. It consists of two separate DNA plasmids: INO-3605, which encodes the H1 hemagglutinin (HA) antigen, and INO-3609, which encodes the H5 HA antigen. The vaccine is administered via intradermal injection followed by electroporation using Inovio's CELLECTRA device, which facilitates the entry of the DNA into host cells. Once inside, the cells express the HA proteins, stimulating both humoral and cellular immune responses against the targeted influenza subtypes. This combination was evaluated in a Phase I clinical trial (NCT01914250) to assess its safety and immunogenicity in healthy adults.
- Other names
- H1 and H5 Influenza Hemagglutinin PlasmidsH-1 and H5 Influenza Hemagglutinin PlasmidsH 1 and H5 Influenza Hemagglutinin Plasmids
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on INO-3605 + INO-3609.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-3605 + INO-3609.